secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001104659-23-125888
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix prices $100.1M public offering; updates wet AMD trial and cash runway into 2027
--------------------------------------------------------------------------------

- Priced underwritten public offering of 30.8M shares at $3.25/share for gross proceeds of $100.1M; net proceeds ~$93.6M.
- Underwriters granted 30-day option for up to 4.62M additional shares; closing expected Dec 18, 2023.
- Submitted SPA amendment to FDA to broaden SOL trial inclusion criteria and test single 450 µg implant; patient enrollment may begin Jan 2024.
- Net proceeds plus existing cash expected to fund operations into 2027; additional capital needed for regulatory approval of AXPAXLI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923125888/0001104659-23-125888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923125888/tm2332876d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-125888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer